Transdermal Estradiol Patches in Locally Advanced Prostate Cancer - PubMed
4 hours ago
- #hormone therapy
- #clinical trial
- #prostate cancer
- Transdermal estradiol (tE2) patches are an alternative to LHRH agonists for androgen-deprivation therapy in prostate cancer.
- The study involved 1360 patients with locally advanced prostate cancer, comparing tE2 patches (100 μg every 24 hours) with LHRH agonists.
- Primary outcome was 3-year metastasis-free survival, with tE2 showing 87.1% vs. 85.9% for LHRH agonists, meeting noninferiority criteria.
- Secondary outcomes included sustained castrate testosterone levels (<1.7 nmol/L) in 85% of patients in both groups.
- 5-year overall survival was 81.1% with tE2 vs. 79.2% with LHRH agonists.
- Side effects: tE2 had fewer hot flashes (44% vs. 89%) but more gynecomastia (85% vs. 42%) compared to LHRH agonists.
- tE2 was noninferior to LHRH agonists, with a better side effect profile except for higher gynecomastia incidence.